Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.EVFM · Entity 8607 | Director | March 31, 2020 | April 01, 2020 |
| GW PHARMACEUTICALS PLCGWPH · Entity 139616 | Director | March 01, 2019 | March 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date March 31, 2020 · Filed April 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 325,000 |
Reported balance
After 2020-03-31 transaction · row 1
1 source rowRow 1 · 2020-03-31 · Exercise / conversion · Acquired 37,500 · Balance 325,000 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-31 · Exercise / conversion · Acquired 37,500 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F2: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 150,000 |
Reported balance
After 2020-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-01 · Grant · Acquired 150,000 · Balance 150,000 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F3: The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019.
F2: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020.
F3: The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021.
GW PHARMACEUTICALS PLC
Report date March 01, 2019 · Filed March 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 16,548 |
Reported balance
After 2019-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-01 · Grant · Acquired 16,548 · Balance 16,548 F1: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3: The exercise price reported is price per ordinary share converted from price per ADS ($172.01). |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-01 | Direct | 3,144 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Grant · Acquired 3,144 · Balance 3,144 F1: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-01 | Direct | 3,144 |
Reported balance
After 2019-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-01 · Grant · Acquired 3,144 · Balance 3,144 F1: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-01 | Direct | 3,144 |
Reported balance
After 2019-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-01 · Grant · Acquired 3,144 · Balance 3,144 F1: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Issuer's Long-Term Incentive Plan.
F2: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer.
F3: The exercise price reported is price per ordinary share converted from price per ADS ($172.01).
F4: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2020 Filed Apr 1, 2020 16:11 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000073 · wf-form4_158577186560857.xml · derivative · entry 3 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 16:11 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000073 · wf-form4_158577186560857.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 16:11 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000073 · wf-form4_158577186560857.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. Read SEC document |
| December 31, 2019 Filed Dec 31, 2019 20:48 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000219 · wf-form4_157784330245840.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| December 31, 2019 Filed Dec 31, 2019 20:48 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000219 · wf-form4_157784330245840.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 11:55 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-012045 · wf-form4_156994532484636.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 11:55 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-012045 · wf-form4_156994532484636.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. Read SEC document |
| June 30, 2019 Filed Jul 1, 2019 14:42 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000138 · wf-form4_156200652729907.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| June 30, 2019 Filed Jul 1, 2019 14:42 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000138 · wf-form4_156200652729907.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:40 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000047 · wf-form4_155433123601709.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:04 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006328 · doc4.xml · derivative · entry 4 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:04 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006328 · doc4.xml · derivative · entry 3 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:04 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006328 · doc4.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:04 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 16,548 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0000899243-19-006328 · doc4.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,548 Underlying: Ordinary Shares · 16,548 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · security: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($172.01). Read SEC document |
| August 15, 2018 Filed Aug 15, 2018 19:09 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 68,929 | $2.33 | $160,604.57 |
DisclosureSEC source: 0001618835-18-000086 · wf-form4_153437456647358.xml · nonDerivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.25 to $2.39, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 19:09 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 31,071 | $2.10 | $65,249.10 |
DisclosureSEC source: 0001618835-18-000086 · wf-form4_153437456647358.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.098 to $2.10, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:22 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000076 · wf-form4_153324130486945.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,500 Underlying: Common Stock · 85,500 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. The option was awarded in connection with Mr. Lynch's consulting services. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:56 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000046 · wf-form4_153065134806235.xml · derivative · entry 3 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016. F2 · derivative.exercise_date: The restricted stock units vested in full on July 2, 2018. F2 · derivative.expiration_date: The restricted stock units vested in full on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:56 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000046 · wf-form4_153065134806235.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016. F2 · derivative.exercise_date: The restricted stock units vested in full on July 2, 2018. F2 · derivative.expiration_date: The restricted stock units vested in full on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:56 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Exercise / conversionCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000046 · wf-form4_153065134806235.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016. Read SEC document |
| May 08, 2018 Filed May 9, 2018 18:35 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 12,875 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001618835-18-000018 · wf-form4_152590524333829.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-05-08 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Mr. Lynch's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 18:17 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 225,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019671 · doc4.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-03-12 F2 · derivative.exercise_date: Mr. Lynch acquired a vested interest in one hundred twenty-five thousand (125,000) shares of common stock exercisable pursuant to the option effective as of March 12, 2018. The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from April 1, 2018. The option was awarded in connection with Mr. Lynch's consulting services provided to the Issuer. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 18:17 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019671 · doc4.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. Lynch's board services. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 17:05 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock Option (right to buy) · Derivative | 3,850 | Not disclosed Strike: $46.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-004303 · doc4.xml · derivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,850 Underlying: Common Stock · 3,850 shares Expires 2026-10-13 F1 · shares: On January 17, 2018, Issuer completed a merger transaction (the "Merger") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. ("Evofem Operations"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the "Merger Agreement"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock. F2 · shares: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F2 · price: These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018. F3 · derivative.exercise_date: Mr. Lynch's interest in the shares of common stock exercisable pursuant to the option effective as of October 13, 2016 vested in a series of twenty-four (24) successive equal monthly installments commencing on April 1, 2016, such that all shares of common stock of Issuer exercisable pursuant to the option were fully vested as of March 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.